金币
UID100033
帖子
主题
积分5899
注册时间2013-5-24
最后登录1970-1-1
听众
性别保密
|

楼主 |
发表于 2014-11-10 11:51:45
|
显示全部楼层
Nature of non-compliance : Overall 24 deficiencies were observed, including 6 major deficiencies related to: [Major 1] Numerous weaknesses in the quality management system (review of process validation data, documentation, product quality review); [Major 2] Insufficient securisation of the electronic raw data in the Quality Control laboratory (No limitation of access levels, no restriction on the deleting of data, no audit trail, inadequate traceability and archiving practises); [Major 3] Inability of the Quality Control unit to conduct and manage HPLC tests appropriately (e.g. no documentation and justification of deviations from analytical procedures, no detection of analysts errors); [Major 4] Multiple risks of contamination identified in the production areas of Ciclosporin (e.g. no protection of clean equipment outlets, equipment under status “to be used for production” stored dirty for several months, open parts of the final steps exposed in dirty surroundings); [Major 5] Blending of Ciclosporin batch tails without adequate traceability and validation combined with unsuitable sample representativity and traceability; [Major 6] Inappropriate equipment and area qualification (e.g. no qualification for the automatic temperature controllers at the fermentation warehouse, the strain centre for Ciclosporin and the cool storage area for Ciclosporin). |
|